Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

Abstract:

BACKGROUND:Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. AIM:To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study population. METHODS:Adults from Ciudad Juarez with H. pylori infections identified by culture or histology received rabeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g, each b.d. for 7 days. Outcome was assessed by 13C-urea breath test carried out 4+ weeks after treatment. RESULTS:A total of 111 patients were enrolled and evaluated by urea breath test; 102 completed the full 7 days therapy. Two deviated from protocol, and five stopped because of adverse events. The cure rate (intention-to-treat) was 85% (95% CI: 78-91%); the per-protocol cure rate was 85% (95% CI: 78-91%). Side-effects were not serious and only 6.6% of those with adverse events stopped medication. Only three isolates were clarithromycin-resistant and none was cured. Compliance explained most of the successes. CONCLUSIONS:In the study population a 7-day rabeprazole triple eradication therapy was both effective and well-tolerated. Clarithromycin resistance was uncommon. We observed a slightly better outcome but consistent with results from recent large studies in US populations.

journal_name

Aliment Pharmacol Ther

authors

Cardenas VM,Graham DY,El-Zimaity HM,Opekun AR,Campos A,Chavez A,Guerrero L

doi

10.1111/j.1365-2036.2006.02755.x

subject

Has Abstract

pub_date

2006-01-15 00:00:00

pages

295-301

issue

2

eissn

0269-2813

issn

1365-2036

pii

APT2755

journal_volume

23

pub_type

杂志文章
  • Review article: COVID-19 and liver disease-what we know on 1st May 2020.

    abstract:BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15813

    authors: Garrido I,Liberal R,Macedo G

    更新日期:2020-07-01 00:00:00

  • The role of hepatitis E virus testing in drug-induced liver injury.

    abstract:BACKGROUND:Locally acquired hepatitis E is an emerging infection in developed countries and can be misdiagnosed as drug-induced liver injury. AIM:To study the role of hepatitis E virus (HEV) testing in drug-induced liver injury. METHODS:Retrospective review of a cohort of patients with suspected drug-induced liver in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03504.x

    authors: Dalton HR,Fellows HJ,Stableforth W,Joseph M,Thurairajah PH,Warshow U,Hazeldine S,Remnarace R,Ijaz S,Hussaini SH,Bendall RP

    更新日期:2007-11-15 00:00:00

  • Determinants of compliance with colonoscopy in patients with adenomatous colon polyps in a veteran population.

    abstract:AIM:To determine factors affecting compliance of a follow-up colonoscopy in patients with previously diagnosed adenomatous colon polyps. METHODS:A retrospective review was performed on patients with adenomatous polyps excised between January and December 1998. Twenty-nine clinical factors were assessed in patients gro...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03176.x

    authors: Siddiqui AA,Patel A,Huerta S

    更新日期:2006-12-01 00:00:00

  • Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.

    abstract:AIM:To compare, in a randomized controlled trial, the efficacy and tolerability of two 1-week triple therapies for Helicobacter pylori eradication. METHODS:One hundred and thirty-four consecutive patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive lansoprazole 30 mg once daily, clarith...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01141.x

    authors: Bazzoli F,Zagari RM,Pozzato P,Fossi S,Ricciardiello L,Nicolini G,De Luca L,Berretti D,Alampi G,Di Pietro C,Morelli P,Roda E

    更新日期:2002-01-01 00:00:00

  • Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.

    abstract:BACKGROUND:Proton pump inhibitors (PPIs) are the most commonly used first-line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown. AIMS:To assess the effectiveness of PPI therapy for EoE in real-world practice. METHODS:This cross-sectional study c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15957

    authors: Laserna-Mendieta EJ,Casabona S,Guagnozzi D,Savarino E,Perelló A,Guardiola-Arévalo A,Barrio J,Pérez-Martínez I,Lund Krarup A,Alcedo J,de la Riva S,Rey-Iborra E,Santander C,Arias Á,Lucendo AJ,EUREOS EoE CONNECT Research group

    更新日期:2020-09-01 00:00:00

  • Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients.

    abstract:BACKGROUND:A simulated upper gastrointestinal (UGI) bleed in cirrhotic patients has been shown to induce hyperammonaemia. The kidney was the site of this exaggerated ammoniagenesis with alanine as substrate. Administration of alanine to decompensated cirrhotic patients did not change hepatic gluconeogenesis, but result...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2012.05044.x

    authors: Mpabanzi L,Deutz N,Hayes PC,Dejong CH,Olde Damink SW,Jalan R

    更新日期:2012-04-01 00:00:00

  • Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.

    abstract:AIM:To assess the efficacy of a prokinetic agent in the long-term treatment of chronic intestinal dysmotility and the influence of extrinsic denervation. METHODS:We assessed symptoms, compliance and untoward effects in an open, 1-year trial of cisapride, 20 mg t.d.s., in 37 patients with neuropathic forms of chronic i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.0953-0673.1996.00403.x

    authors: Camilleri M,Balm RK,Zinsmeister AR

    更新日期:1996-06-01 00:00:00

  • Practice patterns for the evaluation and treatment of eosinophilic oesophagitis.

    abstract:BACKGROUND:Although consensus guidelines for eosinophilic oesophagitis have been published, it remains unclear whether gastroenterologists follow these recommendations. AIM:To assess academic and community practice patterns for the evaluation and treatment of eosinophilic oesophagitis and to compare these practices wi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04476.x

    authors: Peery AF,Shaheen NJ,Dellon ES

    更新日期:2010-12-01 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract:BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13950

    authors: Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期:2017-04-01 00:00:00

  • Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?

    abstract::Summary In patients with gastro-oesophageal reflux disease, the pH of refluxed gastric contents has a direct bearing on disease severity and oesophageal damage. A pH of 4 has been defined as a threshold below which refluxed gastric contents become injurious to the oesophagus. Studies in patients with erosive oesophagi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02140.x

    authors: Armstrong D

    更新日期:2004-10-01 00:00:00

  • Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.

    abstract:BACKGROUND:The hepatic venous pressure gradient (HVPG) is an invasive, but important diagnostic and prognostic marker in cirrhosis with portal hypertension (PHT). During cirrhosis, remodelling of fibrotic tissue by matrix metalloproteinases (MMPs) is a permanent process generating small fragments of degraded extracellu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12484

    authors: Leeming DJ,Karsdal MA,Byrjalsen I,Bendtsen F,Trebicka J,Nielsen MJ,Christiansen C,Møller S,Krag A

    更新日期:2013-11-01 00:00:00

  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract:BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2007.03583.x

    authors: Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期:2008-02-15 00:00:00

  • Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children.

    abstract:BACKGROUND:Recent genome-wide association studies based on adult and paediatric populations have implicated >30 genes/loci as susceptibility loci for Crohn's disease (CD). AIMS:To investigate whether reported genes/loci were also associated with CD in Canadian children. DESIGN AND METHODS:A case-control design was im...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2010.04294.x

    authors: Amre DK,Mack DR,Morgan K,Israel D,Deslandres C,Seidman EG,Lambrette P,Costea I,Krupoves A,Fegury H,Dong J,Grimard G,Levy E

    更新日期:2010-06-01 00:00:00

  • Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients.

    abstract:BACKGROUND:Anti-TNFα biologics induce and maintain remission in inflammatory bowel disease (IBD). Also, they have been reported to induce or unmask idiopathic inflammatory demyelinating disease of the central nervous system (IIDD). AIM:To determine if anti-TNFα biologics increased the risk of IIDD in a large cohort of...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12997

    authors: De Felice KM,Novotna M,Enders FT,Faubion WA,Tremaine WJ,Kantarci OH,Raffals LE

    更新日期:2015-01-01 00:00:00

  • Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

    abstract:BACKGROUND:The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. AIM:To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantag...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2003.01462.x

    authors: Caprilli R,Cottone M,Tonelli F,Sturniolo G,Castiglione F,Annese V,Papi C,Viscido A,Cammà C,Corrao G,Latella G

    更新日期:2003-02-15 00:00:00

  • Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.

    abstract:BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00509.x

    authors: Mönkemüller KE,Hirschowitz BI

    更新日期:1999-05-01 00:00:00

  • Effects on the rat oxyntic mucosa of the histamine2-antagonist loxtidine and the H+, K(+)-ATPase inhibitor omeprazole.

    abstract::The present study examined whether histamine could affect the growth of the enterochromaffin-like (ECL) cell and the parietal cell. The effects of the unsurmountable histamine H2-receptor antagonist loxtidine (80 mg/kg) and the H+, K(+)-ATPase inhibitor omeprazole (100 mumol/kg) were compared in female Sprague-Dawley ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1992.tb00055.x

    authors: Brenna E,Waldum HL,Sandvik AK,Schulze Søgnen B,Kristensen A

    更新日期:1992-06-01 00:00:00

  • Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis.

    abstract:BACKGROUND:Pregabalin has a broad spectrum of analgesic and antihyperalgesic activity in both basic and clinical studies. However, its mechanisms and sites of action have yet to be determined in humans. AIMS:To assess the antinociceptive effect of pregabalin on experimental gut pain in patients with visceral hyperalge...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2011.04802.x

    authors: Olesen SS,Graversen C,Olesen AE,Frøkjaer JB,Wilder-Smith O,van Goor H,Valeriani M,Drewes AM

    更新日期:2011-10-01 00:00:00

  • Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.

    abstract:BACKGROUND:Abnormal barrier function may be genetically determined in Crohn's disease. AIM:To examine the role of abnormal intestinal permeability in genetic predisposition in multiplex vs. sporadic Crohn's disease families. METHODS:Intestinal permeability was measured in patients, relatives and partners by means of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2006.02916.x

    authors: D'Incà R,Annese V,di Leo V,Latiano A,Quaino V,Abazia C,Vettorato MG,Sturniolo GC

    更新日期:2006-05-15 00:00:00

  • Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children.

    abstract:BACKGROUND:Although not currently recommended, dioctahedral smectite (smectite) is commonly used to treat acute infectious diarrhoea in many countries. AIM:To evaluate systematically the effectiveness of smectite in treating acute infectious diarrhoea in children. METHODS:Using medical subject headings and free-langu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2006.02760.x

    authors: Szajewska H,Dziechciarz P,Mrukowicz J

    更新日期:2006-01-15 00:00:00

  • Systematic review: microscopic colitis.

    abstract:BACKGROUND:Collagenous and lymphocytic colitis are fairly common causes of chronic non-bloody diarrhoea, especially in elderly female. AIM:To present a systematic review of microscopic colitis. METHODS:A PubMed search using the MeSH terms microscopic colitis, collagenous colitis, lymphocytic colitis and chronic diarr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02913.x

    authors: Nyhlin N,Bohr J,Eriksson S,Tysk C

    更新日期:2006-06-01 00:00:00

  • Non-alcoholic fatty liver diseases and risk of colorectal neoplasia.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis. AIM:To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD. METHODS:A total of 26 540 asymptomatic a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13866

    authors: Ahn JS,Sinn DH,Min YW,Hong SN,Kim HS,Jung SH,Gu S,Rhee PL,Paik SW,Son HJ,Gwak GY

    更新日期:2017-01-01 00:00:00

  • Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.

    abstract:BACKGROUND:Few studies have evaluated interferon and ribavirin therapy in hepatitis C virus-infected patients with persistently normal alanine aminotransferase (ALT) levels. AIM:To determine the efficacy and safety of combination therapy in this population, and to evaluate the impact of treatment on health-related qua...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02819.x

    authors: Bini EJ,Mehandru S

    更新日期:2006-03-15 00:00:00

  • Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat.

    abstract:BACKGROUND:Many experiments have indicated that the gut glucagons (enteroglucagons) are associated with cell proliferation in the small intestine. However, recent studies have failed to show trophic effects of glicentin (enteroglucagon) on the intestine. AIMS:To examine the effects of glicentin on intestinal prolifera...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01082.x

    authors: Sasaki M,Fitzgerald AJ,Mandir N,Sasaki K,Wright NA,Goodlad RA

    更新日期:2001-10-01 00:00:00

  • Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.

    abstract:BACKGROUND:Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. AIM:To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. METHODS:Eleven patients (10%) diagnosed with fulminant...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02894.x

    authors: Miyake Y,Iwasaki Y,Terada R,Onishi T,Okamoto R,Sakai N,Sakaguchi K,Shiratori Y

    更新日期:2006-05-01 00:00:00

  • Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.

    abstract:BACKGROUND:Optimal management approach is not well defined for subjects who fail initial first- and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists. AIM:To evaluate the efficacy and safety of standard and 'rescue' eradication therapies at primary and second...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02210.x

    authors: Qasim A,Sebastian S,Thornton O,Dobson M,McLoughlin R,Buckley M,O'Connor H,O'Morain C

    更新日期:2005-01-01 00:00:00

  • Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease generally has a benign course; however, patients with non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma. Currently, there is a lack of consensus about optimal NASH treatment. AIM:To assess the efficacy of insulin-sensitizing agents ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2010.04467.x

    authors: Rakoski MO,Singal AG,Rogers MA,Conjeevaram H

    更新日期:2010-11-01 00:00:00

  • Review article: definition and diagnosis in portal hypertension--continued problems with the Baveno consensus?

    abstract::The goals of the Baveno workshops were to develop consensus definitions of key events related to portal hypertension and variceal bleeding, and to produce guidelines to facilitate the conduct and reporting of clinical trials. The consensus definitions concern the diagnosis of active bleeding, failure to control bleedi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02108.x

    authors: de Franchis R

    更新日期:2004-09-01 00:00:00

  • Gastrointestinal symptoms before and during menses in women with IBD.

    abstract:BACKGROUND:It is believed that women with inflammatory bowel disease (IBD) have heightened symptoms around their menses. However, there is little information regarding normative changes and which symptoms emerge in relation to menses. AIM:To determine the relationship between gastrointestinal and other symptoms and me...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05155.x

    authors: Bernstein MT,Graff LA,Targownik LE,Downing K,Shafer LA,Rawsthorne P,Bernstein CN,Avery L

    更新日期:2012-07-01 00:00:00

  • Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) and irritable bowel syndrome may occur more often than expected by chance, but little community data exists and risk factors are unknown. AIM:To determine prevalence and risk factors for overlap of GERD and irritable bowel disease. METHODS:Population-based, cross-se...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2007.03366.x

    authors: Jung HK,Halder S,McNally M,Locke GR 3rd,Schleck CD,Zinsmeister AR,Talley NJ

    更新日期:2007-08-01 00:00:00